3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Sarcoma
1
Gastrointestinal
1
Breast
1
Conditions
Sarcoma
6
Sarcoma, Ewing
4
Neoplasm Metastasis
2
Lymphoma
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Rhabdomyosarcoma, Embryonal
1
Rhabdomyosarcoma, Alveolar
1
Rhabdomyosarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroectodermal Tumors, Primitive
1
Neoplasms
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Insulin-Like Growth Factor I, Resistance To
1
Interventions
Cyclophosphamide
17
pembrolizumab
12
Doxorubicin
10
fludarabine
7
Irinotecan
7
Blood Specimen Collection
7
Temozolomide
6
Gemcitabine
6
Etoposide
6
Radiotherapy
5
Ifosfamide
5
Carboplatin
5
Albumin-Bound Paclitaxel
5
tecogalan
4
cemiplimab
4
Vincristine
4
Trabectedin
4
Paclitaxel
4
Nivolumab
4
Filgrastim
4
Drug Therapy
4
Dexamethasone
4
Bevacizumab
4
pazopanib
3
olaparib
3
nilotinib
3
dostarlimab
3
aflibercept
3
Therapeutics
3
Taxes
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
ganitumab
×
Sarcoma
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled